Universität zu Köln

Persa, Oana-Diana and Mauch, Cornelia (2020). What is new in the diagnosis and therapy of malignant melanoma? Dtsch. Med. Wochenschr., 145 (24). S. 1754 - 1757. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-4413

Full text not available from this repository.

Abstract

Melanoma incidence and mortality rates are increasing. The sentinel lymph node biopsy plays an important prognostic role and is pivotal for the decision to undergo an adjuvant therapy making it an important diagnostic tool. The lack of survival benefit in patients with sentinel lymph node-positive (SLN+) melanoma upon immediate complete lymphadenectomy (CLND) suggest a parallel and not stepwise development of lymph node metastasis and distant metastasis thus questioning the role of immediate CLND. These findings also suggest adjuvant therapy may play a more important role for SLN+ melanoma patients than CLND. Recently, the PD-1 inhibitor Nivolumab and Pembrolizumab as well as the BRAF/MEK inhibitor Dabrafenib and Trametinib were approved for the adjuvant therapy of stage III malignant melanoma. Another novelty in the therapy of malignant melanoma is the approval of the first oncolytic virus, Talimogene laherparepvec, for the treatment of unresectable stage III and IV (M1a) melanoma. Significant progress has also been made in the treatment of patients with cerebral melanoma metastasis since studies indicate that both BRAF/MEK inhibitors and the immunotherapy with CTLA4 and PD-1 inhibitors are efficient in this group of patients. With this wide range of possible systemic therapies for advanced melanoma further studies regarding therapy sequence, combinations between targeted therapies and immunotherapy as well as biomarkers for treatment response are needed to help guide physicians find the optimal therapy for patients with advanced malignant melanoma.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Persa, Oana-Diana UNSPECIFIED UNSPECIFIED UNSPECIFIED Mauch, Cornelia UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-310251
DOI:	10.1055/a-1012-2972
Journal or Publication Title:	Dtsch. Med. Wochenschr.
Volume:	145
Number:	24
Page Range:	S. 1754 - 1757
Date:	2020
Publisher:	GEORG THIEME VERLAG KG
Place of Publication:	STUTTGART
ISSN:	1439-4413
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language DABRAFENIB PLUS TRAMETINIB; STAGE-III; BRAF(V600)-MUTANT; PLACEBO Multiple languages Medicine, General & Internal Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/31025